Literature DB >> 11039423

Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial.

R Brunner1, R A Widder, P Walter, C Lüke, E Godehardt, K U Bartz-Schmidt, K Heimann, H Borberg.   

Abstract

PURPOSE: Membrane differential filtration is able to optimize rheologic parameters by eliminating high molecular weight proteins and lipoproteins from the blood. Following the hypothesis that these changes result in an improvement of the microcirculation, the authors tested the efficacy of membrane differential filtration in improving visual function in patients with age-related macular degeneration (ARMD).
METHODS: Forty patients (40 eyes) were randomized into two groups. The treatment group was treated five times over a period of 21 weeks. In both groups, 9/20 of the eyes showed subfoveolar subretinal neovascularization. The main parameter of the study was visual acuity (VA). Electroretinogram (ERG), electrooculogram, and macular visual evoked potentials were also recorded. Plasma and whole blood viscosity and erythrocyte aggregation were measured.
RESULTS: The 20 patients treated repeatedly over a period of 21 weeks showed a mean improvement of 0.63 lines (SD 1.8) of VA on Early Treatment Diabetic Retinopathy Study charts. The control group showed a deterioration of 0.94 lines (SD 1.7) compared to VA at baseline examination. The amplitude of the ERG photopic a-wave and the flicker ERG was significantly increased. The rheologic parameters were lowered in all treated patients.
CONCLUSION: Repetitive treatment with membrane differential filtration is able to improve visual acuity of patients with ARMD and the natural course of this disease. Several questions arise from the results of this study. Further research will show if it is possible to optimize the selection of patients for subgroups with predictive responses through morphologic and functional tests and how to create an optimized and individual treatment strategy determined by the quality, intensity, and frequency of treatment sessions.

Entities:  

Mesh:

Year:  2000        PMID: 11039423     DOI: 10.1097/00006982-200009000-00009

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

Review 1.  Current and future treatment options for nonexudative and exudative age-related macular degeneration.

Authors:  Grant M Comer; Thomas A Ciulla; Mark H Criswell; Michael Tolentino
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

2.  Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results.

Authors:  Jose S Pulido; Jeffrey L Winters; David Boyer
Journal:  Trans Am Ophthalmol Soc       Date:  2006

3.  Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART.

Authors:  Michael Janusz Koss; Peter Kurz; Theoharis Tsobanelis; Walter Lehmacher; Cordula Fassbender; Reinhard Klingel; Frank H J Koch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-23       Impact factor: 3.117

Review 4.  [Rheopheresis for age-related macular degeneration].

Authors:  C Wild; S Mathis; B Guba; G Gartlehner
Journal:  Ophthalmologe       Date:  2009-02       Impact factor: 1.059

5.  Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.

Authors:  Jose S Pulido
Journal:  Trans Am Ophthalmol Soc       Date:  2002

6.  TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD.

Authors:  Francis E Cangemi
Journal:  BMC Ophthalmol       Date:  2007-02-26       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.